Adolphe Rothschild Ophtalmologic Foundation   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Geneva Switzerland (2005)

Organization Overview

First Clinical Trial
2010
NCT01155986
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Fondation A. de Rothschild | Fondation Ophtalmologique A. de Rothschild | Fondation Ophtalmologique Adolphe de Rothschild | Fondation Ophtalmologique Adolphe de Rotschild, Service de Neurochirurgie, CEntre d'Evaluation et de Traitement de la Douleur | Fondation Ophtalmologique de Rothschild | Fondation Rothschild Paris | Head of Department Ophthalmological Foundation A. de Rothschild, Paris, France | Hopital Fondation A de Rothschild | Hôpital Fondation A de Rothschild | Hôpital Fondation A. de Rothschild | Paris (FR), Adolphe Rothschild Ophtalmologic Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Aneurysm (Phase 3)

Blood Coagulation Disorders (Phase 4)

Brain Injuries (Phase 4)

Cataract (Phase 4)

Chronic Pain (Phase 2)

Hemorrhage (Phase 4)

Hemostatic Disorders (Phase 4)

Hypoxia (Phase 4)

Intracranial Aneurysm (Phase 3)

Intracranial Hemorrhages (Phase 4)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Neuralgia (Phase 2)

Olfaction Disorders (Phase 3)

Pain, Postoperative (Phase 2)

Parkinson Disease (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Retinal Neoplasms (Phase 2)

Retinal Telangiectasis (Phase 3)

Retinoblastoma (Phase 3)

Sclerosis (Phase 4)

Syndrome (Phase 3)

Telangiectasis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 31